Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
- PMID: 33870839
- DOI: 10.1080/14728214.2021.1916468
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
Abstract
Introduction: Triple-negative breast cancer accounts for 10-20% of invasive breast cancers and is characterized by an aggressive phenotype and poor outcomes in the early and advanced settings compared to other breast cancer subtypes. Chemotherapy continues to be the mainstay of treatment, but recent advances have demonstrated the benefit of adding immune checkpoint inhibitors (ICIs) to chemotherapy regimens for patients with both early and advanced TNBC, particularly if PD-L1-positive. Despite these results, further improvements are needed.Areas covered: This review covers immunotherapy drugs which have recently completed, involved in ongoing or due to start phase II trials. This includes approaches to augment the response to existing ICIs, next-generation ICIs, combination treatments with targeted agents and drugs that target the tumor microenvironment. Potential development issues are also discussed.Expert opinion: The field of immunotherapy is developing rapidly and holds great promise for patients with TNBC. Promising avenues of research currently in phase II trials include targeting multiple immune checkpoints simultaneously and the addition of phosphatidylinositol 3-kinase (PI3K)/AKT inhibitors to ICI/chemotherapy regimens. A better understanding of the immunosuppressive role played by the tumor microenvironment has also been important. However, challenges remain, particularly regarding the need for more effective predictive biomarkers.
Keywords: Advanced TNBC; early TNBC; immune checkpoint; immunotherapy; targeted therapies; tumor microenvironment.
Similar articles
-
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024. Front Immunol. 2024. PMID: 39735530 Free PMC article. Review.
-
Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.Breast Cancer. 2025 Jul;32(4):676-688. doi: 10.1007/s12282-025-01707-5. Epub 2025 May 6. Breast Cancer. 2025. PMID: 40327275 Free PMC article. Review.
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.Expert Opin Investig Drugs. 2022 Jun;31(6):531-548. doi: 10.1080/13543784.2022.1986002. Epub 2021 Oct 11. Expert Opin Investig Drugs. 2022. PMID: 34569400 Free PMC article. Review.
-
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4. Curr Treat Options Oncol. 2021. PMID: 33743085 Review.
-
Current usage of pembrolizumab in triple negative breast cancer (TNBC).Expert Rev Anticancer Ther. 2024 May;24(5):253-261. doi: 10.1080/14737140.2024.2341729. Epub 2024 Apr 16. Expert Rev Anticancer Ther. 2024. PMID: 38594892 Review.
Cited by
-
Mesenchymal Stem Cells and Selenium Nanoparticles Synergize with Low Dose of Gamma Radiation to Suppress Mammary Gland Carcinogenesis via Regulation of Tumor Microenvironment.Biol Trace Elem Res. 2023 Jan;201(1):338-352. doi: 10.1007/s12011-022-03146-1. Epub 2022 Feb 9. Biol Trace Elem Res. 2023. PMID: 35138531 Free PMC article.
-
Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.Int J Mol Sci. 2025 Feb 7;26(4):1396. doi: 10.3390/ijms26041396. Int J Mol Sci. 2025. PMID: 40003864 Free PMC article. Review.
-
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.Cancers (Basel). 2021 Dec 9;13(24):6209. doi: 10.3390/cancers13246209. Cancers (Basel). 2021. PMID: 34944829 Free PMC article. Review.
-
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.Future Oncol. 2025 Mar;21(6):715-735. doi: 10.1080/14796694.2025.2461443. Epub 2025 Feb 12. Future Oncol. 2025. PMID: 39936282 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials